# PRESS RELEASE 2006

## Dongbao to acquire Ferring’s Malmö manufacturing operation  
By [pulse](/content/author/pulse/index.html) on 17 November 2006  
Ferring Pharmaceuticals and Shanghai Dongbao Biopharmaceutical Company announced today the signing of an agreement by which Dongbao Biopharmaceutical will purchase Ferring’s manufacturing operation at Malmö in Sweden…

## Symposium looks at potential of mesalazine to prevent colorectal cancer in IBD  
By [pulse](/content/author/pulse/index.html) on 24 October 2006  
Speaking today at a Ferring-sponsored symposium on the occasion of the 14th United European Gastroenterology…

## Ferring Pharmaceuticals Officially Opens Its Production Site and Global Administrative Headquarters  
By [pulse](/content/author/pulse/index.html) on 06 July 2006  
Ferring Pharmaceuticals, the pioneering Swiss pharmaceutical group and world leader in industrial synthesis of peptides, today officially opens its new production site and administrative Headquarters in Saint-Prex in the canton of Vaud…

## Assisted Reproductive Technology helps address demographic challenge in Europe  
By [pulse](/content/author/pulse/index.html) on 19 June 2006  
New research conducted by the independent ‘think tank’ RAND Europe discusses one potential solution to the population ageing crisis in Europe that has not yet been considered…

## Degarelix, a novel GnRH blocker from Ferring, moves into phase III  
By [pulse](/content/author/pulse/index.html) on 07 April 2006  
Following the presentation today of the results of the Phase IIb programme with degarelix in prostate cancer, which are in line with previous promising studies, Ferring Pharmaceuticals announced the immediate start of Phase III trials…

## Ferring and Astellas enter a license agreement on Degarelix for the treatment of prostate cancer in Japan  
By [pulse](/content/author/pulse/index.html) on 31 January 2006  
Ferring Pharmaceuticals (“Ferring”; headquarters: Lausanne, Switzerland; executive chairman: Frederik Paulsen) and Astellas Pharma Inc…